130 related articles for article (PubMed ID: 10428209)
1. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand.
Ambar BB; Frei K; Malipiero U; Morelli AE; Castro MG; Lowenstein PR; Fontana A
Hum Gene Ther; 1999 Jul; 10(10):1641-8. PubMed ID: 10428209
[TBL] [Abstract][Full Text] [Related]
2. Expression of mutant non-cleavable Fas ligand on retrovirus packaging cells causes apoptosis of immunocompetent cells and improves prodrug activation gene therapy in a malignant glioma model.
Nafe C; Cao YJ; Quinones A; Dobberstein KU; Kramm CM; Rainov NG
Life Sci; 2003 Aug; 73(14):1847-60. PubMed ID: 12888123
[TBL] [Abstract][Full Text] [Related]
3. Fas ligand/Fas-mediated apoptosis in human coronary artery smooth muscle cells: therapeutic implications of fratricidal mode of action.
Belanger AJ; Scaria A; Lu H; Sullivan JA; Cheng SH; Gregory RJ; Jiang C
Cardiovasc Res; 2001 Sep; 51(4):749-61. PubMed ID: 11530108
[TBL] [Abstract][Full Text] [Related]
4. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
Hoves S; Krause SW; Halbritter D; Zhang HG; Mountz JD; Schölmerich J; Fleck M
J Immunol; 2003 Jun; 170(11):5406-13. PubMed ID: 12759415
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral vectors encoding tumor necrosis factor-alpha and FasL induce apoptosis of normal and tumoral anterior pituitary cells.
Candolfi M; Jaita G; Pisera D; Ferrari L; Barcia C; Liu C; Yu J; Liu G; Castro MG; Seilicovich A
J Endocrinol; 2006 Jun; 189(3):681-90. PubMed ID: 16731798
[TBL] [Abstract][Full Text] [Related]
6. FasL gene knock-down therapy enhances the antiglioma immune response.
Jansen T; Tyler B; Mankowski JL; Recinos VR; Pradilla G; Legnani F; Laterra J; Olivi A
Neuro Oncol; 2010 May; 12(5):482-9. PubMed ID: 20406899
[TBL] [Abstract][Full Text] [Related]
7. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
8. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in glioma cells by recombinant human Fas ligand.
Kawaguchi S; Mineta T; Ichinose M; Masuoka J; Shiraishi T; Tabuchi K
Neurosurgery; 2000 Feb; 46(2):431-8; discussion 438-9. PubMed ID: 10690733
[TBL] [Abstract][Full Text] [Related]
10. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
11. Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions.
Mano T; Luo Z; Suhara T; Smith RC; Esser S; Walsh K
Hum Gene Ther; 2000 Aug; 11(12):1625-35. PubMed ID: 10954897
[TBL] [Abstract][Full Text] [Related]
12. Death of solid tumor cells induced by Fas ligand expressing primary myoblasts.
Hofmann A; Blau HM
Somat Cell Mol Genet; 1997 Jul; 23(4):249-57. PubMed ID: 9542527
[TBL] [Abstract][Full Text] [Related]
13. Gene transfer of Fas ligand induces tumor regression in vivo.
Arai H; Gordon D; Nabel EG; Nabel GJ
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13862-7. PubMed ID: 9391118
[TBL] [Abstract][Full Text] [Related]
14. Fas-mediated apoptosis is involved in the elimination of gene-transduced hepatocytes with E1/E3-deleted adenoviral vectors.
Okuyama T; Li XK; Funeshima N; Fujino M; Sasaki K; Kita Y; Kosuga M; Takahashi M; Saito H; Suzuki S; Yamada M
J Gastroenterol Hepatol; 1998 Sep; 13 Suppl():S113-8. PubMed ID: 9792044
[TBL] [Abstract][Full Text] [Related]
15. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms.
Kafrouni MI; Brown GR; Thiele DL
J Immunol; 2001 Aug; 167(3):1566-74. PubMed ID: 11466378
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
Li X; Liu YH; Zhang YP; Zhang S; Pu X; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5463-73. PubMed ID: 17875776
[TBL] [Abstract][Full Text] [Related]
17. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity.
Morelli AE; Larregina AT; Smith-Arica J; Dewey RA; Southgate TD; Ambar B; Fontana A; Castro MG; Lowenstein PR
J Gen Virol; 1999 Mar; 80 ( Pt 3)():571-583. PubMed ID: 10091995
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer.
Fleck M; Zhang HG; Kern ER; Hsu HC; Müller-Ladner U; Mountz JD
Arthritis Rheum; 2001 Apr; 44(4):964-73. PubMed ID: 11315936
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated transfer of Fas ligand gene augments radiation-induced apoptosis in U-373MG glioma cells.
Shinoura N; Yamamoto N; Asai A; Kirino T; Hamada H
Jpn J Cancer Res; 2000 Oct; 91(10):1044-50. PubMed ID: 11050476
[TBL] [Abstract][Full Text] [Related]
20. Induction of FAS ligand expression in a human hepatoblastoma cell line by HCV core protein.
Ruggieri A; Murdolo M; Rapicetta M
Virus Res; 2003 Nov; 97(2):103-10. PubMed ID: 14602201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
